Ascend Laboratories, Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Ascend Laboratories, Llc Pharmaceutical Import Records from India — 25 Products, $163.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ascend Laboratories, Llc — Pharmaceutical Importer Profile (2026) | 25 Products, $163.5M Trade | TransData Nexus

Ascend Laboratories, Llc

Pharmaceutical Importer · United States · Cardiovascular Focus · $163.5M Total Trade · DGFT Verified

Ascend Laboratories, Llc is a pharmaceutical importer based in United States with a total trade value of $163.5M across 25 products in 12 therapeutic categories. Based on 3,590 verified import shipments from Indian Customs (DGFT) records, Ascend Laboratories, Llc is the #1 buyer in 2 products including Tacrolimus, Colchicine. Ascend Laboratories, Llc sources from 4 verified Indian suppliers, with Alkem Laboratories Limited accounting for 93.1% of imports.

Ascend Laboratories, Llc — Import Portfolio & Supplier Network

Ascend Laboratories, Llc import network — 25 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ascend Laboratories, Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Alkem Laboratories Limited	$126.4M	4,327	93.1%
Granules India Limited	$4.7M	110	3.5%
Inventia Healthcare Limited	$4.6M

What Formulations Does Ascend Laboratories, Llc Import?

Formulation	Value	Ships
Pharmaceutical products: metformin hcl	$1.4M	39
Pharmaceutical products:metformin hcl	$1.3M	33
Pharmaceutical products metformin hcl	$1.1M	24
Ibuprofen tablets USP 600MG (500's)	$934.5K	20
Pharmaceutical products:cholestyramine	$882.4K	27
Pharmaceutical products - cephalexin 500MG CAPS (500's)	$830.5K	19
Pharmaceutical products: amlodipine	$828.9K	41
Pharmaceutical products: ezetimibe	$742.9K	19
Metformin hydrochloride tablets USP	$700.0K	14
Pharmaceutical products : amlodipine besylate TAB 10MG(1000's) us ndc	$692.3K	23
Pharmaceutical products: finasteride TAB	$661.2K	16
Pharmaceutical products:mycophenolate	$621.3K	13
Pharmaceutical products - cefdinir capsules USP 300MG (60's	$600.0K	12
Pharmaceutical products: mycophenolate	$583.2K	12
Pharmaceutical products : metformin	$556.1K	13

Ascend Laboratories, Llc imports 2,217 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 25 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metformin	Diabetes & Endocrine	$24.3M	485	2.7%	4
2	Cephalexin	Antibiotics	$24.1M	482	0.1%	3
3	Amlodipine	Cardiovascular	$20.4M	586	0.1%	4
4	Gabapentin	CNS & Psychiatric	$19.3M	385	1.0%	8
5	Ibuprofen	Analgesics & Antipyretics	$17.1M	343	1.9%	5
6	Ezetimibe	Lipid & Metabolism	$11.7M	265	1.0%	3
7	Mycophenolate	Immunosuppressants	$9.2M	183	0.8%	8
8	Cefuroxime	Advanced Antibiotics	$5.5M	109	0.1%	2
9	Tacrolimus	Immunosuppressants	$5.4M	125	1.1%	1
10	Ras	Ayurvedic & Herbal Products	$3.5M	69	1.1%	17
11	Everolimus	Immunosuppressants	$3.2M	64	4.9%	2
12	Nifedipine	Cardiovascular	$2.9M	70	1.9%	11
13	Sirolimus	Immunosuppressants	$2.6M	53	3.7%	4
14	Telmisartan	Cardiovascular	$2.3M	68	0.0%	11
15	Mesalamine	Gastrointestinal	$2.3M	45	0.1%	13
16	Famotidine	Gastrointestinal	$1.9M	43	1.8%	7
17	Linezolid	Advanced Antibiotics	$1.8M	35	2.3%	4
18	Simvastatin	Cardiovascular	$1.4M	65	0.6%	12
19	Lansoprazole	Gastrointestinal	$1.1M	22	0.4%	11
20	Capecitabine	Advanced Oncology	$900.0K	18	0.6%	2
21	Itraconazole	Antifungals	$850.0K	17	0.9%	15
22	Colchicine	Lipid & Metabolism	$750.0K	15	3.6%	1
23	Metoprolol	Cardiovascular	$650.0K	13	0.1%	4
24	Minocycline	Advanced Antibiotics	$571.5K	28	1.5%	10
25	Fosfomycin	Advanced Antibiotics	$94.5K	2	0.7%	6

Ascend Laboratories, Llc imports 25 pharmaceutical products across 12 categories into United States totaling $163.5M. The company is the #1 buyer for 2 products: Tacrolimus, Colchicine.

Ascend Laboratories, Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ascend Laboratories, LLC is a U.S.-based pharmaceutical company specializing in the development, manufacturing, and distribution of generic medications. Established in the early 2000s, Ascend initially focused on assisting other companies in developing off-patent medicines for the generic market. In 2008, the company launched its first three products under its own label, marking its entry into the U.S. market. Headquartered at 339 Jefferson Road, Suite 101, Parsippany, New Jersey, Ascend Laboratories operates as a wholly owned subsidiary of ThePharmaNetwork, LLC, which is itself a subsidiary of S & B Holdings S.a.r.l., a wholly owned subsidiary of Alkem Laboratories Limited, a leading Indian pharmaceutical company. This strategic alignment with Alkem Laboratories provides Ascend with access to world-class research and development, advanced manufacturing capabilities, and a robust international supply chain, enhancing its position in the U.S. pharmaceutical distribution network.

2Distribution Network

Ascend Laboratories' distribution network is designed to ensure efficient delivery of its pharmaceutical products across the United States. While specific warehouse locations are not publicly disclosed, the company's strategic partnerships and affiliations suggest a well-established logistics infrastructure capable of nationwide coverage. The collaboration with Alkem Laboratories further strengthens this network, leveraging Alkem's global supply chain to facilitate the importation and distribution of finished pharmaceutical formulations. This integration allows Ascend to maintain a steady supply of high-quality generic medications to meet the demands of hospitals, pharmacies, and wholesalers throughout the U.S.

3Industry Role

In the U.S. pharmaceutical supply chain, Ascend Laboratories functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from India, particularly from its parent company Alkem Laboratories, Ascend plays a crucial role in introducing generic medications to the U.S. market. The company's focus on importing finished dosage forms, such as tablets, capsules, syrups, and injections, aligns with the regulatory requirements set forth by the U.S. Food and Drug Administration (FDA) for imported drugs. This strategic approach enables Ascend to offer a diverse portfolio of generic drugs, contributing to the accessibility and affordability of essential medications in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ascend Laboratories, Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ascend Laboratories demonstrates a high degree of sourcing concentration, with 93.1% of its total import value from India attributed to a single supplier, Alkem Laboratories Limited. This significant reliance indicates a strategic choice to leverage Alkem's extensive research and development capabilities, advanced manufacturing facilities, and established regulatory compliance. The substantial volume of shipments—4,327 out of 4,630 total shipments—suggests a stable and long-term partnership, likely characterized by favorable terms and consistent product quality. However, such concentration also presents potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges within Alkem Laboratories. To mitigate these risks, Ascend may consider diversifying its supplier base or establishing contingency plans to ensure uninterrupted access to critical pharmaceutical products.

2Supply Chain Resilience

The resilience of Ascend Laboratories' supply chain is closely tied to its dependence on Alkem Laboratories Limited for the majority of its imported pharmaceutical formulations. While this partnership offers advantages in terms of product quality and regulatory compliance, it also exposes Ascend to potential vulnerabilities. The limited number of suppliers—four in total—suggests a lack of diversification, which could be a concern in the event of supply chain disruptions. Additionally, the concentration of shipments from a single supplier increases the impact of any operational or regulatory issues faced by Alkem Laboratories. To enhance supply chain resilience, Ascend Laboratories might explore partnerships with additional suppliers, particularly those with complementary product portfolios, and develop contingency plans to address potential disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for the safety, efficacy, and quality of drugs imported into the U.S. For foreign drug establishments, including those in India, the FDA mandates registration and listing of all drug products intended for importation. This process involves submitting an entry notice and an entry bond to U.S. Customs, pending FDA's decision regarding the admissibility of the product. Additionally, the FDA requires that all imported drugs comply with specific labeling requirements, including informative and truthful labeling in English, to ensure that consumers receive accurate information about the medications they use.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Foreign manufacturers must register their establishments with the FDA and list all drug products intended for importation. This registration process ensures that the FDA is notified of all regulated products imported into the U.S. and facilitates the agency's review of the products' admissibility. Regarding Good Manufacturing Practice (GMP) certification, the FDA recognizes GMP standards from various international regulatory bodies, including the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Manufacturers from India seeking to export pharmaceutical products to the U.S. must ensure that their facilities comply with these recognized GMP standards to meet FDA requirements. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the U.S., ensuring that all intermediaries in the supply chain adhere to regulatory standards.

Ascend Laboratories, Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ascend Laboratories' product strategy focuses on importing a diverse range of generic medications across various therapeutic areas, including cardiovascular, diabetes and endocrine, and antibiotics. This approach addresses significant health issues prevalent in the U.S. population, such as hypertension, diabetes, and infectious diseases. The company's emphasis on these therapeutic categories aligns with market demand, as there is a continuous need for affordable and effective treatments in these areas. By sourcing these products from India, Ascend leverages the country's robust pharmaceutical manufacturing capabilities and cost advantages, enabling the company to offer high-quality generics at competitive prices.

2Sourcing Profile

Ascend Laboratories' sourcing strategy is centered on importing finished pharmaceutical formulations from India, primarily from its parent company, Alkem Laboratories Limited. This focus on finished dosage forms, such as tablets, capsules, syrups, and injections, allows Ascend to meet the regulatory requirements for imported drugs in the U.S. The company's preference for sourcing from India is driven by the country's established reputation for high-quality pharmaceutical manufacturing and its ability to produce cost-effective generics. This sourcing strategy enables Ascend to offer a broad portfolio of generic medications to the U.S. market, enhancing access to essential treatments for patients.

Frequently Asked Questions — Ascend Laboratories, Llc

What products does Ascend Laboratories, Llc import from India?

Ascend Laboratories, Llc imports 25 pharmaceutical products across 12 categories. Top imports: Metformin ($24.3M), Cephalexin ($24.1M), Amlodipine ($20.4M), Gabapentin ($19.3M), Ibuprofen ($17.1M).

Who supplies pharmaceuticals to Ascend Laboratories, Llc from India?

Ascend Laboratories, Llc sources from 4 verified Indian suppliers. The primary supplier is Alkem Laboratories Limited (93.1% of imports, $126.4M).

What is Ascend Laboratories, Llc's total pharmaceutical import value?

Ascend Laboratories, Llc's total pharmaceutical import value from India is $163.5M, based on 3,590 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ascend Laboratories, Llc focus on?

Ascend Laboratories, Llc imports across 12 categories. The largest: Cardiovascular (16.9%), Diabetes & Endocrine (14.8%), Antibiotics (14.7%).

Get Full Ascend Laboratories, Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 6 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Ascend Laboratories, Llc

Ascend Laboratories, Llc — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Ascend Laboratories, Llc?

What Formulations Does Ascend Laboratories, Llc Import?

What Products Does Ascend Laboratories, Llc Import?

Top Products by Import Value

Ascend Laboratories, Llc Therapeutic Categories — 12 Specializations